NasdaqGS:TEMLife Sciences
Tempus AI Expands Oncology Portfolio With HRD-RNA And Lung Screening Deal
Tempus AI (NasdaqGS:TEM) has launched its HRD-RNA algorithm, designed to identify Homologous Recombination Deficiency in cancer using RNA data.
The company also announced a partnership with Median Technologies to bring the eyonis LCS AI lung cancer screening tool to markets in the US and Europe.
Tempus AI, which last closed at $55.41, is adding new tools to its precision oncology and early detection portfolio with the HRD-RNA algorithm and the eyonis LCS AI screening partnership. The stock...